Board summary
Key figures
59,801
Registered population
61.1% aged 18–64
18.1%
Aged 65+
ICB 14.9% · England 17.9%
52.7%
In IMD quintile 1
ICB 40.7% · England 21.0%
~30,218
Core20 residents (est.)
Resident basis; registered basis ~32,660 · see page 3
9,589
Hypertension register
+8.08% in 3 yrs · England +5.60%
595
SMI register
16.6% of Wigan (LAD)'s
1,759
COPD register
Reviews +0.07% in 3 yrs
Forecast to 2030
11,459
Hypertension patients, 2030
+1,870 on today
72.6%
QRISK ≥20% on statins, 2030
+2.95pp over 3 yrs
4.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension register trails the Wigan borough rate.
Recorded hypertension prevalence is 15.9% versus 18.0% in Wigan, an unadjusted benchmark gap of 1,200 patients that could reflect unverified under-detection.
Age-five pre-school boosters fall below target.
At age 5, 4-in-1 booster coverage is 79.4% (15.6 pp below the 95.0% target) and MMR dose 2 is 84.4% in Q1 2025/26.
Registered hypertension and diabetes control beats England.
Hypertension treatment to target reaches 75.1% (England 70.3%) and non-frail diabetes HbA1c control reaches 60.7% (England 57.4%) among registered patients.
Population, age and ethnicity
Older patients make up 18.1% of registrations while projected population growth is 1.2%
LEIGH PCN has 59,801 registered patients. Patients aged 65+ represent 18.1% (10,795), compared with 18.8% in Wigan (LAD), 14.9% in NHS Greater Manchester Integrated Care Board, and 17.9% in England. Those aged 0–17 comprise 20.8% (12,442), against 20.0% in Wigan (LAD), 21.8% in the ICB, and 19.6% in England. Projected list growth to 2030 is 1.2% under an unverified methodology (Wigan LAD 1.1%, ICB 1.6%, England 2.3%). Census resident estimates show 0.1% Gypsy or Irish Traveller and 0.2% Roma. Registered patient counts and Census populations use distinct bases.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Wigan (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wigan LA) | 2,706 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wigan LA) | 1,243 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wigan LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 52.7% of the list, with all ten practices exceeding England
In Leigh PCN, 52.7% of registered patients live in Core20 areas, above Wigan (29.4%), the ICB (40.7%) and England (21.0%). The weighted practice rate of 54.6% shows a 1.94 percentage point discrepancy. Concentration ranges from 41.4% at Westleigh Medical Practice to 67.6% at Leigh Family Practice. In volume, Leigh Family Practice (6,759 estimated patients) and Lilford & Pennington Park Surgery (4,183) hold the largest caseloads. Targeting preventive checks by patient volume may help reach the largest Core20 populations.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
595
SMI register
0.99% recorded prevalence
430
Learning disability register
0.71% recorded prevalence
9
Care homes, 524 beds
In the PCN catchment
10.1%
Provide unpaid care
Wigan (LAD), Census 2021
The PCN records 595 severe mental illness patients (1.0%) and 430 on the learning disability register (0.7%, above England's 0.6%), representing 19% of the borough register. Catchment assets include 9 care homes with 524 beds. Wigan recorded 11 rough sleepers in 2025; borough counts cannot be extrapolated to PCN lists.
Severe mental illness: physical health checks
SMI prevalence is 1.0% (England 1.0%, Wigan (LAD) 1.0%). Annual blood pressure checks reached 86.2% (England 83.4%) and BMI recording reached 84.8% (England 82.1%). Captured check elements are separate and do not confirm complete physical health checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,589
Hypertension register
+8.08%
Register growth, 3 yrs
Wigan (LAD) +10.59% · England +5.60%
+2.52pp
BP control, under 80
≤140/90 · +4.20pp aged 80+
+1,870
More patients by 2030
Forecast 11,459 (18.54%)
Hypertension case-finding and control
Recorded hypertension prevalence is 15.9% (9,589 patients), exceeding England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%) but below Wigan (LAD) (18.0%). Between 2023 and 2025, recorded prevalence changed +8.1% (England +5.6%, Wigan (LAD) +10.6%). Treatment processes show 91.5% had a recent blood pressure check and 75.1% are treated to target, above England (70.3%) and the ICB (71.4%). Against borough prevalence, an unadjusted benchmark comparison indicates a gap of 1,200 patients across an unadjusted range of -481 to +1,200. Lower recorded prevalence than the borough benchmark may reflect population age structure or case finding differences that clinical audit could test.
Lipids and statins
For primary prevention, 66.3% of patients with QRISK ≥ 20% receive lipid-lowering therapy, above England (63.6%) and Wigan (LAD) (64.0%) but below NHS Greater Manchester Integrated Care Board (67.0%). From 2023 to 2025, therapy changed +4.7% (England +6.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 112,525 | £2.20 | £1.94 | £1.86 | £247,555 |
| Cardiovascular (all), 2025 | 147,633 | £4.25 | £3.15 | £3.33 | £627,440 |
The PCN prescribed 112,525 lipid-regulating drug items in 2026, representing £247,555 annual spend. Cost per item was £2.20, exceeding England (£1.86) and NHS Greater Manchester Integrated Care Board (£1.94). The PCN spent £38,258 more than at England's unit cost and £29,256 more than at the ICB's.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.63%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.82%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.9% (1,759 patients), above Wigan (LAD) (2.6%), NHS Greater Manchester Integrated Care Board (2.3%) and England (1.9%), changing +16.8% between 2023 and 2025 (England +2.6%). The COPD review rate was 76.3% (changing +0.1% versus England +2.8%). Asthma prevalence is 7.4% (4,211 patients), above England (6.6%), with a 65.5% review rate leaving about 1,500 unreviewed patients. Asthma prescribing for ages 5–19 reached 2,431 items per 1,000 (England 1,488), while second-hand smoke status recording for ages 6–19 was 74.8% (England 78.8%).
Cancer register and children's immunisation
The cancer register records 2,095 patients (3.5% prevalence, England 3.8%). In Q1 2025/26, 6-in-1 coverage at 24 months was 95.2%. At age 5, MMR dose 1 coverage was 94.4%, while dose 2 was 84.4%, a 10 pp difference between doses in the same cohort. Pre-school 4-in-1 booster coverage was 79.4%, below the 95.0% target by 15.6 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage (6,491 of 11,679) across NHS Greater Manchester ICB were diagnosed at stage 1 or 2, comparable to England (55.3%) but below the 75.0% national ambition by 19.4 pp. Staged cancers represented 70.8% of 16,492 registered cases, above England's 67.0%. Between 2013 and 2022, the ICB early-stage share rose +3.1 pp from 52.4%, yet reaching 75.0% requires about 2,270 additional early diagnoses annually. Early detection varies by site, from 82.5% in breast to 40.4% in lung and 22.4% in oesophagus. Staging reflects regional pathways, not PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
| Pathways within standard (%) | Wrightington, Wigan and Leigh | Bolton | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.80 | 80.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 89.04 | 96.50 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.78 | 69.66 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wrightington, Wigan and Leigh | Bolton | Manchester | England |
|---|---|---|---|---|
| MRI | 0.49 | 2.05 | 11.68 | 21.40 |
| CT | 7.78 | 19.40 | 14.66 | 9.92 |
| Echocardiography | 24.37 | 3.48 | 4.91 | 28.48 |
| Colonoscopy | 6.10 | 1.33 | 4.51 | 30.83 |
| Gastroscopy | 12.54 | 2.06 | 29.35 | 29.02 |
| All 15 DM01 tests | 14.36 | 15.78 | 8.98 | 23.14 |
| Community services activity | Wigan residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 48,150 | 573,310 |
| Referrals | 13,750 | 94,470 |
| Patients with a contact | 18,695 | 183,535 |
Community services (residents of Wigan), Jun 2026 (provisional). In provisional community services returns for June 2026, adults aged 65 and over accounted for 58.5% of all community contacts among borough residents (28,190 of 48,150 contacts). Older residents account for the majority of community activity across the borough, though these figures describe local authority residents rather than PCN-level activity.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, overall QOF achievement was 90.4% at Leigh Family Practice, while Westleigh Medical Practice achieved 98.2% (England: 92.5%). For QOF vaccination and immunisation-domain achievement, Leigh Family Practice achieved 15.6% (England: 55.2%), whereas Westleigh Medical Practice achieved 83.8%, reflecting a range of 68.2 pp. This wide variation may indicate preventative care disparities, which audits of individual uptake could test.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Premier Health | 124 | 50.2 | 86.2% | 64.9% | 91.7% |
| The Avenue Surgery | 121 | 60.4 | 88.4% | 66.9% | 90.5% |
| Grasmere Surgery | 115 | 44.9 | 87.9% | 85.2% | 90.4% |
| Foxleigh Family | 105 | 59.8 | 90.3% | 79.8% | 85.1% |
| Old Henry Street | 103 | 63.2 | 76.3% | 84.0% | 81.2% |
| Lilford & | 113 | 60.0 | 69.1% | 77.1% | 76.8% |
| Brookmill | 113 | 48.1 | 67.2% | 78.0% | 75.9% |
| Leigh Sports | 100 | 43.7 | 56.7% | 82.1% | 74.6% |
| Leigh | 102 | 67.6 | 66.1% | 78.9% | 70.1% |
| Westleigh Medical | 107 | 41.4 | 51.1% | 68.2% | 61.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Diabetes control rose +13.0% over three years, while dementia register growth trailed England
Over three years, diabetes HbA1c control rose +13.0% (England +4.4%, ICB +6.2%), with current control at 60.7% versus England's 57.4%. In contrast, dementia register growth trailed at +4.8% over three years, below England (+6.0%) and Wigan (+7.6%). Heart failure reviews rose +11.1% over three years (England +8.7%), though current review coverage at 76.1% remains below England (78.5%) and the ICB (80.0%). Slower register expansion and trailing review levels are consistent with variation in case identification and recall, which local clinical audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Diabetes statin (no CVD)
QRISK statin treatment
Diabetes statin (CVD)
Dementia register
Diabetes HbA1c control
BMI record (SMI)
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wigan (LAD) | Asset | PCN | Wigan (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 9 (524 beds) | n/a | Schools (catchment) | 38 | n/a |
| Children's centres | 4 | 20 | Places of worship | 29 | 164 |
| Libraries | 1 | 10 | Primary schools (LA maintained) | 15 | 68 |
| Primary academies | 4 | 21 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Opportunistic hypertension case-finding audit
Recorded hypertension prevalence is 15.9% (9,589 patients), below Wigan (LAD) at 18.0% (+1,200 patients unadjusted; range -481 against England's 15.2% to +1,200). For discussion, practices could run electronic searches for patients with repeated raised blood pressure readings without a hypertension code and offer opportunistic checks. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured asthma review and recall
On the 4,211-patient asthma register (7.4% prevalence), 65.5% had a review in 12 months (ICB 66.2%, England 65.7%), leaving 1,451 (about 1,500) unreviewed. For discussion, the PCN could run structured recall using a single review template, checking inhaler prescribing and second-hand smoke exposure during after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 160), age-5 MMR2 was 84.4% (10.6 pp below the 95.0% target; 10 pp below MMR1 at 94.4%) and 4-in-1 was 79.4% (15.6 pp below 95.0%, England 80.9%). Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 clinical outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Hypertension case finding review (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Urgent cancer referral safety netting (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Opportunistic hypertension case-finding audit (p12) | Hypertension register · Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured asthma review and recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
